Eye Insert Missed Its Main Vision Goal in a Late Stage Trial but Cut Injections Sharply

EyePoint’s DURAVYU missed its primary vision endpoint in the LUGANO trial for wet AMD, despite reducing injection burden by 42 percent.

Have A Referral?